Level V Evidence

Platelet-Rich Plasma: The PAW Classification System

Jeffrey M. DeLong, B.Sc., Ryan P. Russell, M.A., and Augustus D. Mazzocca, M.S., M.D.

Abstract: Platelet-rich plasma (PRP) has been the subject of hundreds of publications in recent years. Reports of its effects in tissue, both positive and negative, have generated great interest in the orthopaedic community. Protocols for PRP preparation vary widely between authors and are often not well documented in the literature, making results difficult to compare or replicate. A classification system is needed to more accurately compare protocols and results and effectively group studies together for meta-analysis. Although some classification systems have been proposed, no single system takes into account the multitude of variables that determine the efficacy of PRP. In this article we propose a simple method for organizing and comparing results in the literature. The PAW classification system is based on 3 components: (1) the absolute number of Platelets, (2) the manner in which platelet Activation occurs, and (3) the presence or absence of White cells. By analyzing these 3 variables, we are able to accurately compare publications.

Despite the promising effects of platelet-rich plasma (PRP) therapy, most studies conducted have lacked accurate measurements and documentation of the PRP components and delivery methods used. This lack of standardization and consistency is prevalent throughout the literature and has frustrated attempts to compare results between articles. To determine the efficacy of PRP from system to system and patient to patient, the PRP components and the means by which they are delivered to the target tissue site should be identified and documented.[1] Without these fundamental prerequisites,

the evolution of PRP as a safe and effective treatment for orthopaedic disorders may not progress efficiently.

IDENTIFYING CONTENT OF PRP

Several essential factors exist that need to be identified to adequately determine the effects of PRP treatment.

- The most essential factor is to ensure accurate and definitive concentration measurements of platelets. Without precise quantification of the cellular components, validation and accurate comparison of studies will remain extremely difficult, ultimately impeding discovery of optimum dosing. Many studies published in the recent literature lack this most basic requirement.
- The presence or absence of platelet activators, as well as the type of activator used, is another important element requiring documentation. The way in which the platelets are applied to the tissue will undoubtedly affect the response of the tissue. For example, an exogenous platelet activator may be necessary to generate a clot in certain procedures, whereas endogenous platelet activation without the use of an external clotting factor may be ideal in other indications.
- Whether the administered PRP treatment includes highly concentrated leukocytes above baseline

TABLE 1. *Plasma-Based and Buffy Coat–Based PRP Systems*

Device Name	Centrifuge Time (min)	Initial Blood Volume (mL)	Final PRP Volume (mL)	Platelet Concentration From Baseline	WBC Content	References
Plasma-based PRP systems						
Arthrex (Naples, FL)/ ACP (Edison, NJ)	5	16	4-7	2×-3×	Minimal to none	22
Cascade/MTF Fibrinet	6 (plasma) 21 (clot)	9	4.5 (plasma) 2 (clot)	1.3×-1.7× (plasma)	Minimal to none	14, 23-25
BTI (Vitoria-Gasteiz, Spain)/ PRGF	8	9	2-3	2×-3×	Minimal to none	26-28
Buffy coat–based PRP systems						
Biomet (Warsaw, IN) GPS II/III	12-15	30 or 60	3 or 6	2×-8×	Increased over baseline	29-33
Harvest (Plymouth, MA) SmartPReP 2/DePuy (Warsaw, IN) Symphony II	12-15	20 or 60	3 or 7-10	3×-7×	Increased over baseline	24, 32-35
Arteriocyte Medtronic (Minneapolis, MN)/Magellan	14-20	30 or 60	3-10	3×-7×	Increased over baseline	14, 33, 36, 37
Emcyte (Fort Myers, FL)/ Genesis CS/Exactech (Gainsville, FL) Accelerate	12	30 or 60	3 or 10	7×-10×	Increased over baseline	38-40

Abbreviations: ACP, autologous conditioned platelets; BTI, Biotechnology Institute; GPS, gravitational platelet separation; MTF, musculoskeletal transplant foundation; PRGF, platelet rich growth factor.

levels or leukocyte-deficient PRP below baseline should also be documented. This will identify which type of PRP system was used, plasma based or buffy coat. Buffy-coat systems contain both red blood cells (RBCs) and white blood cells (WBCs), whereas plasma-based systems exclude them. There is considerable debate over the necessity of including white cells, with several studies suggesting that they may in fact be harmful to the healing process.[2-11] Neutrophils, in particular, have been hypothesized to impede healing. It is likely that the need to include WBCs in the PRP preparation will vary by indication, and the WBC concentration should be noted as above or below baseline in the "Methods" section of articles. Further identifying neutrophil levels above or below baseline may prove to be a key in solving the controversy surrounding the efficacy of PRP rich in leukocytes.

• In addition to documentation of the components of the PRP end product, it is also important to record the delivery technique and whether additional factors were distributed to the tissue site.

UNDERSTANDING PRP METHODS AND SYSTEMS

PRP can be manufactured in 2 basic formats: plasma-based and buffy-coat preparations. Both begin with whole blood but differ in the centrifugation process, which isolates and concentrates different blood-cell components.[12]

Plasma-based methods work to isolate only plasma and platelet components and remove WBCs. Protocols for these preparations leave some platelets behind and focus on intentionally excluding leukocytes, which are thought to be detrimental to the healing process.[2-11] The main goal of this method is to capture only platelets during the centrifugation; thus a slower and shorter spin regimen is used. This yields platelet concentrations typically around 2× to 3× those of baseline whole blood levels (300,000 to 500,000 platelets/μL) (Table 1).

Buffy coat–based methods isolate a platelet-poor plasma layer and a buffy-coat layer, which contains both leukocytes and erythrocytes. Protocols for buffy-coat systems seek to capture all available platelets during the centrifugation and obtain a high concentration of WBCs; thus high spin rates and long spin regimens are used. Leukocytes and RBCs are harvested in an effort to obtain the highest platelet concentration levels possible. The typical platelet concentration yields are between 3× and 8× those of baseline levels (500,000 to 1,500,000 platelets/μL) (Table 1).

To complicate comparisons, each commercially available PRP system uses a different spin protocol. Protocols, number and length of spins, platelet and leukocyte concentrations, and delivery platform vary between these

devices, making no 2 PRP products identical (Table 1). These variances lead to different amounts of anabolic and catabolic proteins released to the target tissues after injection.[13] For instance, Castillo et al.[14] tested 3 different PRP separation systems, and each system yielded a similar platelet concentration (approximately 600,000 platelets/μL) and RBC, active transforming growth factor (TGF) β1, and fibrinogen levels. However, each system produced significantly different levels of platelet-derived growth factor (PDGF) AB, PDGF-BB, vascular endothelial growth factor (VEGF), and WBC concentration. Although the effects of these bioactive factors on tissue were not tested, it is possible that these variations could result in considerable and dramatically distinct effects on healing.[12] Lack of standardization of PRP preparations may therefore lead to inconsistent results in the literature.[15]

Additives also alter the content and effect of PRP. For example, anticoagulants and local anesthetics alter the pH of PRP; understanding the effect of this alteration on tissue response is important. Variations in pH have been shown to affect in vitro proliferation, and consideration must be given to the desired response before choosing to mix PRP with an additive.[16,17] Local anesthetics, in particular, appear to produce a negative effect on PRP treatment in vitro and should be avoided when possible.[17,18]

PRP can even be altered by the metals used in medical devices or implants as well as the centrifuge material. Tanaka et al.[19] studied the effects that various metals had on platelet adhesion. The study found that platelet adhesion and aggregation can both be inhibited and enhanced by different types of metal. Test tube materials are also important. Michelson[20] reported in his comprehensive book on platelets that polypropylene tubes are superior to either polystyrene or polycarbonate when used for platelet preparation and/or storage. In addition, he noted that uncoated glass may artificially activate platelets and affect results.[20] A study conducted by Grottum et al.[21] determined the effect of polystyrene particles on PRP. Incubation of PRP with polystyrene particles induced surface contact between platelets and particles, uptake of particles, and changes in platelet morphology. After injection into rabbits, Grottum et al. identified increased platelet aggregation, which may have resulted from a reduction in platelet surface charge due to interaction with polystyrene.[21] For these reasons, it is imperative that the protocol chosen to manufacture PRP in each study be strictly adhered to, and materials cannot be freely substituted.

UNDERSTANDING CELLULAR COMPONENTS

Platelet Concentration

Few studies have compared the healing effects of different PRP platelet concentrations for the same indication.[14,41] This may prove to be the most significant aspect in identifying the true effectiveness of PRP and in choosing the proper protocol.

Low: Less Than 1× (Less Than Baseline): Platelet concentrations below baseline may not allow for a sufficient cellular response.[42] Often used as a control, platelet-poor plasma has only shown the slightest benefit.

Moderate: Greater Than 1× to Less Than 4× (Greater Than Baseline to 750,000 platelets/μL): Plasma-based PRP systems typically produce platelet concentrations between baseline and 3× baseline. The absolute platelet number obtained by this method is generally equal to or less than 750,000 platelets/μL.

In vitro, in vivo, and clinical studies have been conducted and published by Anitua and Sánchez, as well as their colleagues, showing the effectiveness of PRP with a platelet concentration of 2× to 3×.[26,28,43-49] Sánchez et al.[28] injected exogenously activated PRP with a 3× platelet concentration into surgically repaired human Achilles tendons. They found significant improvement and an earlier return to sports as compared with the control group. The same researchers performed an uncontrolled retrospective case study in which they treated 16 aseptic nonunions intraoperatively with a moderate PRP platelet concentration (2× to 3×) with a bone allograft and an autologous fibrin membrane. All subjects went on to bony union.[47] Another study showed enhanced tendon graft ligamentization during anterior cruciate ligament surgery.[41] Histology at the 6- and 24-month marks showed increased connective tissue remodeling when compared with the untreated grafts.

Anitua and Sánchez are not the only researchers who have shown positive responses to PRP in the 2× to 3× baseline range. Graziani et al.[50] evaluated the effect of PRP on the function of osteoblasts and fibroblasts. After a 72-hour incubation period, the 2.5× (approximately 550,000 platelets/μL) PRP group resulted in a statistically significant increase in cell count for osteoblasts and fibroblasts when compared with plasma and the negative control. The authors concluded that a platelet concentration of 2.5× yielded optimal results. In addition, Torricelli et al.[51] evaluated the effect of PRP for the treatment of musculoskeletal overuse injuries in competition horses. With the placebo effect nullified, they found that PRP with a platelet concentration of 750,000 plate-

lets/μL accelerated healing and allowed an earlier return to competition.

High: 4× to 6× (>750,000 to 1,800,000 platelets/ μL): Literature suggests that successful buffy coat– based PRP treatments typically produce platelet concentrations greater than 3× and primarily in the 4× to 6× range.[14,24,32] The absolute platelet number is generally greater than 750,000 to 1,800,000 platelets/μL. Successful reports in this range include that of He et al.,[52] who found accelerated bone healing with PRP platelet concentrations of approximately 4× to 5× versus controls in patients who underwent transformational lumbar interbody fusions. An in vivo rabbit study conducted by Weibrich et al.[53] analyzed the effect of platelet count in PRP on bone regeneration. They found significant bone regeneration with a platelet concentration up to 6× (1,729,000 platelets/μL). Giusti et al.[54] studied endothelial cells and found that the optimal concentration for cell proliferation was 1,500,000 platelets/μL.

Super: Greater Than 6× (>1,800,000 platelets/ μL): Concentrations too high may be detrimental. Overwhelming the healing milieu with an excessive amount of platelets may lead to apoptosis, growth factor receptor downregulation, and receptor desensitization, which may result in a paradoxical inhibitory effect.[42,55] Several studies have shown this. Weibrich et al.[53] showed that highly concentrated platelets (6× to 11×) (1,845,000 to 3,200,000 platelets/μL) had an inhibitory effect on osteoblast activity when compared with lower concentrations. In a study on alveolar bone cells, Choi et al.[56] concluded that the high concentration of platelets used may have resulted in adverse effects on bone growth.

Platelet Count

A single individual's platelet count can vary considerably on different days.[18] There is also a significant variation in platelet count between individuals. For example, the normal platelet count varies between 150,000 and 350,000 platelets/μL. An individual with a low normal count receiving PRP with a concentration of 1 million platelets/μL would see an approximate 6.5× increase. An individual with a high normal count receiving PRP with a concentration of 1 million platelets/μL would see an approximate 3× increase. Variations in an individual's baseline platelet count lead to inconsistency in quantifying a "fold" increase, making PRP products different between both individuals and treatments, even when identical protocols are used. For this reason, documenting both the absolute number of platelets per microliter contained in the PRP preparation and the individual's own platelet count on the day of treatment is important in comparing effectiveness.

Centrifugation force, duration, and frequency are also important elements that may result in varying platelet concentrations and alteration of platelet morphology.[57] Jo et al.[58] determined optimum PRP gel formation by varying time and gravitational forces during centrifugation. The optimal conditions were found to be 900g for 5 minutes and 1,500g for 15 minutes for the separating centrifugation step and the condensing centrifugation step, respectively. In addition, Barrett and Erredge[59] found that the number of centrifugations varied platelet capture significantly. They determined that a single centrifugation spin produced 1,254,000 platelets/μL whereas a double spin produced 2,017,000 platelets/μL.

The process for measuring platelet count may contribute to variation as well. Most hematology analyzer systems are designed to operate in ranges found within whole blood, and PRP may exceed the upper limit of the linear range of platelets that can be counted. In addition, adequate resuspension of the PRP and proper sample preparation are required for accurate platelet counts. Platelet clumping or lack of even distribution may result in inaccuracies.[1]

Woodell-May et al.[1] determined the average platelet count to be significantly less when samples were measured immediately after preparation of the PRP than when samples were resuspended on a rocker ($P < .05$). This study suggests that for accurate platelet counts to be achieved, the entire PRP sample must be removed and allowed to sit on a rocker for at least 5 minutes before counting. Furthermore, this study recommends using manual mode in the hematology analyzer because automatic counting modes are more likely to allow the sample to settle, reducing the absolute platelet count.[32]

Leukocyte Content

The effect of highly concentrated WBCs contained within PRP preparations[60] has been hotly debated. PRP systems that use a buffy coat contain an increased concentration of WBCs above baseline levels, whereas plasma-based methods do not. Although normal levels of WBCs have a positive immunomodulatory effect, heightened levels in some PRP preparations may have a deleterious impact. Literature suggests that excessive leukocytes, specifically neutrophils, may be contributing to these undesired results.[2-11] However, the efficacy of WBCs in PRP treatments still remains unclear and may be

dependent on indication. PRP used to treat open wounds and prevent infection may require supranormal WBC levels,[61-64] whereas PRP used to minimize scar formation should not contain WBCs.[7,65] WBC content should always be documented in any classification system.

UNDERSTANDING DELIVERY METHOD

Activation Methods

Platelets can be activated endogenously or through the addition of an exogenous clotting factor to any commercially available system. Each type of activator may produce varying effects and significantly influence growth factor kinetics. Accurately documenting the delivery method and activation scheme used is another key to a successful classification system.

Exogenous: Exogenous activation results in rapid coagulation of platelets and quick clot formation. For this reason, clots formed in this manner are best applied manually to the tissues, rather than administered by injection. They often can be sutured to repairs. Proposed benefits of a preformed clot include the ability to more accurately localize growth factor release, as well as decreased diffusion when used intra-articularly. Advocates of preclotted PRP also theorize a more sustained growth factor release because growth factors are thought to elute from the clot slowly over the span of several days. The effect of exposure of the clot to synovial fluid has not been well documented, and it is possible that the clot is quickly dissolved in the joint.[66,67]

Endogenous: The addition of external clotting factors to PRP may not be needed to significantly activate platelets. Not only will tissue collagen cause activation of platelets but simple agitation of platelets, such as centrifugation, as well as needle-induced bleeding during PRP injection, may provide the appropriate endogenous clotting factors needed for activation. Endogenous activation has the potential for slower aggregation of platelets and release of growth factors by allowing collagen within the tissue to operate as the activator providing a natural release pattern.[68] Clot formation occurring after injection provides the benefit of administration through a needle and may allow a more precise delivery to, and within, the target tissue.

Platelet Activators

Thrombin: Thrombin causes rapid aggregation of platelets. Rapid activation may lead to excessive con-

densing of the fibrin matrix and significant retraction of clots, which may be inferior with respect to cell migration and growth factor enmeshment when compared with less condensed physiological activation.[69-72] A rapid activation may also lead to a decrease in the total amount of growth factors available at the tissue site over time. Some growth factors have a short half-life (minutes to hours) and will degrade before additional tissue receptors become available if they are not immediately used upon release from a platelet.[68,73] Additional potential negative effects include an immune-mediated coagulopathy resulting from antibody formation against bovine-derived thrombin.[68]

Calcium Chloride: Calcium chloride has been added exogenously to PRP preparation in lieu of bovine thrombin and may result in the formation of a less condensed fibrin matrix. The fibrin matrix may provide a trapping mechanism for platelets, resulting in smaller amounts of thrombin formation endogenously, allowing a slower release of growth factors over a 7-day period, which may enhance cell migration and healing.[72,74,75] Injections containing calcium chloride have a low pH and cause significant pain and a burning sensation to the patient.

Calcium Chloride Plus Thrombin: Calcium chloride is a citrate inhibitor and allows the plasma to coagulate, and thrombin causes fibrin to polymerize into an insoluble gel; platelets then degranulate and release growth factors.[57] When calcium chloride and thrombin are combined with PRP, a gel or scaffold matrix is produced. This may offer the benefit of a slower, "time-released" effect of growth factors.

Type I Collagen: Endogenous type I collagen has been found to be equally effective as thrombin in activating platelets and stimulating the release of growth factors. In an in vitro study of PRP from human donors, clotting was performed with type I collagen or bovine thrombin. Type I collagen resulted in similar release of PDGF and VEGF but a more extended and overall greater release of TGF-β than thrombin. Clots formed by use of type I collagen also exhibited far less retraction than those formed with bovine thrombin. In addition, both type I collagen and bovine thrombin stimulated similar release of PDGF and VEGF between days 1 and 10, whereas thrombin resulted in a greater release of TGF-β during days 1 to 5.[76]

Delivery Technique

The technique used during delivery of PRP is another fundamental variable that should be understood and addressed. Individual tissues may have ideal an-

TABLE 2. *Types of PRP Delivery*

PRP Platform	Specific Activator/Modality
Liquid injection	Endogenous
	$CaCl_2$
Spray	Endogenous
	$CaCl_2$ + thrombin
	Thrombin
Gel	$CaCl_2$ + thrombin
	Thrombin
Clot (fibrin matrix)	$CaCl_2$ + centrifugation
	$CaCl_2$ + thrombin
	Thrombin

Abbreviation: $CaCl_2$, calcium chloride.

atomic locations for delivery of PRP. For example, PRP injection into the osseotendinous, midsubstance, or myotendinous zone of a tendon may produce varying results.[46] An in vivo rabbit model study determined the effect of PRP on insulin-like growth factor (IGF) 1 expression in the epitenon and endotenon of rabbit Achilles tendons. At week 4, histologic analysis showed superior expression of IGF-1 in the epitenon of the PRP group versus the saline solution group, which produced superior IGF-1 levels in the endotenon ($P < .0001$).[77]

The PRP delivery platform (liquid, spray, gel, or clot) should be selected based on procedure type (open

v arthroscopic) and whether slow or fast activation of platelets is desired (Table 2).

PAW CLASSIFICATION SYSTEM

With all of the previous information being taken into consideration, the PAW classification system of PRP is based on 3 components: (1) the absolute number of Platelets, (2) the manner in which platelet Activation occurs, and (3) the presence or absence of White cells. By analyzing these 3 variables, we are able to accurately compare publications (Tables 3 and 4).

Platelets and White Cells

The first part of the classification system identifies the specific cellular components of platelets and white cells contained within the PRP preparation and should be documented as follows (Fig 1). Platelet concentration should be measured in platelets per microliter and categorized as follows: P1, less than or equal to baseline levels; P2, greater than baseline levels to 750,000 platelets/μL; P3, greater than 750,000 to 1,250,000 platelets/μL; and P4, greater than 1,250,000 platelets/μL.

Total WBC content is identified as either above (A) or below/equal to (B) baseline levels. Systems designated with an "A" are buffy-coat systems, whereas plasma-based systems fall under "B." Because the

TABLE 3. *PAW Classification of Plasma-Based Systems and Buffy Coat–Based Systems*

Device Name	Platelet Concentration	Activation Method*	WBCs Total WBC Content	WBCs Neutrophil Content	PAW Classification Endogenous	PAW Classification Exogenous	References
Plasma-based systems							
Arthrex/ACP	P2	*	B	β	P2-Bβ	P2-x-Bβ	22
Cascade/MTF Fibrinet	P2	*	B	β	P2-Bβ	P2-x-Bβ	14, 23-25
BTI/PRGF	P2	*	B	β	P2-Bβ	P2-x-Bβ	26-28
Buffy coat–based systems†							
Biomet GPS II/III	P2	*	A	α	P2-Aα	P2-x-Aα	29-33
	P3				P3-Aα	P3-x-Aα	
	P4				P4-Aα	P4-x-Aα	
Harvest SmartPReP 2/DePuy Symphony II	P2	*	A	α	P2-Aα	P2-x-Aα	24, 32-35
	P3				P3-Aα	P3-x-Aα	
	P4				P4-Aα	P4-x-Aα	
Arteriocyte/Medtronic Magellan	P2	*	A	α	P2-Aα	P2-x-Aα	14, 33, 36, 37
	P3				P3-Aα	P3-x-Aα	
	P4				P4-Aα	P4-x-Aα	
Emcyte Genesis CS/Exactech Accelerate	P4	*	A	α	P4-Aα	P4-x-Aα	38-40

*Ultimately, researchers can choose to activate platelets endogenously or through the addition of an exogenous clotting factor to any commercially available system.

†Buffy coat–based systems typically produce highly variable platelet concentrations.

TABLE 4. *PAW Classification of Clinical Studies**

| Condition Treated	Authors	Evidence Level	Study Type	No. of Patients	PRP Outcome	System	Platelets/μL	Activation Method	WBCs	PAW
Medial/lateral epicondylitis	Hechtman et al.[78] (*Orthopedics*, 2011)	IV	Case series, prospective study	PRP group previously unresponsive to nonsurgical treatment (n = 31)	(+) Improved pain and function scores, thus avoiding surgery	Cascade MTF	NA	Exogenous CaCl₂	Below	NA-x-Bβ
	Thanasas et al.[79] (*Am J Sports Med*, 2011)	I	Randomized controlled single-blind trial	PRP group (n = 14) v autologous whole blood group (n = 14)	(+) Effective for chronic lateral elbow epicondylitis	Biomet GPS III	1,292,500 5.5×	Endogenous type I collagen	Above	P4-Aα
	Peerbooms et al.,[80] 1-yr follow-up (*Am J Sports Med*, 2010)	I	Randomized controlled study	PRP group (n = 51) v corticosteroid group (n = 49)	(+) Reduced pain, increased function	Biomet	NA	Endogenous type I collagen	Above	NA-Aα
	Gosens et al.,[81] 2-yr follow-up (*Am J Sports Med*, 2011)	I	Randomized controlled study	PRP group (n = 51) v corticosteroid group (n = 49)	(+) Reduced pain, increased function	Biomet	NA	Endogenous type I collagen	Above	NA-Aα
	Mishra and Pavelko[82] (*Am J Sports Med*, 2006)	II	Prospective comparative study	PRP group (n = 15) v bupivacaine group (n = 5)	(+) Reduced pain in chronic severe tendinosis in patients in whom nonoperative treatment has failed	Biomet GPS	3,310,000 5.39×	Endogenous type I collagen	Above	P4-NA-Aα
Achilles tendinopathy/ rupture	de Vos et al.[66] (*Br J Sports Med*, 2011)	I	Double-blind randomized placebo-controlled study	PRP group (n = 27) v placebo-saline solution injection (n = 27)	(Neutral) PRP injection did not result in greater improvement in pain and activity over placebo injection	Biomet GPS III	NA	Endogenous type I collagen	Above	NA-Aα
	de Jonge et al.,[83] 1-yr follow-up (*Am J Sports Med*, 2011)	I	Double-blind randomized placebo-controlled study	PRP group (n = 27) v placebo-saline solution injection (n = 27)	(Neutral) PRP injection did not result in greater improvement in pain and activity over placebo injection	Biomet GPS III	NA	Endogenous type I collagen	Above	NA-Aα
	Schepull et al.[84] (*Am J Sports Med*, 2011)	II	Randomized controlled single-blind study	PRP group (n = 16) v control group (n = 14)	(–) PRP not useful for treatment of Achilles tendon ruptures; lower Achilles tendon total rupture score, thus suggesting detrimental effect	NA	3,673 ± 1,051 × 10⁹ 17×	Endogenous type I collagen	NA	P4-NA
	Filardo et al.[85] (*Orthopedics*, 2010)	IV	Case study	PRP group (n = 1)	(+) Fast tissue repair and return to full function	NA	6.5 × 10⁶ 6.1× ± 1.6	Exogenous CaCl₂	NA	P4-x-NA
	Sánchez et al.[28] (*Am J Sports Med*, 2007)	III	Case-control, descriptive laboratory study	PRGF athlete group (n = 6)	(+) Earlier ROM recovery and return to activity	BTI/PRGF	NA	Exogenous CaCl₂	Below	NA-x-Bβ
Patellar tendinopathy	Filardo et al.[86] (*Int Orthop*, 2010)	II	Prospective comparative study	PRP group with 3 injections (n = 15) v exercise-only group (n = 16)	(+) PRP has potential to achieve satisfactory clinical outcome, even in difficult cases with chronic refractory tendinopathy after previous classical treatments have failed	NA	6.5 × 10⁶ 6.1× ± 1.6	Exogenous CaCl₂	NA	P4-x-NA
	Kon et al.[87] (*Injury*, 2009)	IV	Prospective study	PRP group (n = 20) evaluated at 6 mo	(+) Aided regeneration of tissue which otherwise has low healing potential	NA	6 × 10⁶ 6×	Exogenous CaCl₂	NA	P4-x-NA
Rotator cuff reconstruction	Jo et al.[88] (*Am J Sports Med*, 2011)	II	Prospective cohort study	PRP group (n = 19) v control group (n = 23)	(Neutral) Did not clearly show accelerated recovery clinically or anatomically (+) However, improvement in internal rotation	COBE spectra LRS Turbo (Lakewood, CO)	1,400 × 10³ (adjusted via saline solution to 1,000 × 10³)	Exogenous Calcium Gluconate	NA	P3-x-NA
	Randelli et al.[89] (*J Shoulder Elbow Surg*, 2011)	I	Prospective randomized controlled study, 2-yr follow-up	PRP augmentation group (n = 26) v control group (n = 27)	(+) Reduced pain in first postoperative months; long-term results of subgroups of grade 1 and 2 tears suggest that PRP positively affected cuff rotator healing	Biomet GPS II	NA	Exogenous CaCl₂ + thrombin	Above	NA-x-Aα

TABLE 4. *Continued*

Condition Treated	Authors	Evidence Level	Study Type	No. of Patients	PRP Outcome	System	Platelets/μL	Activation Method	WBCs	PAW
	Castricini et al.[90] (*Am J Sports Med*, 2011)	I	Randomized controlled study	PRFM group (n = 43) patients with PRFM *v* control group (n = 45)	(Neutral) No statistical difference between groups; study does not support use of autologous PRFM for augmentation of double-row repair of small or medium rotator cuff tear to improve healing of rotator cuff	Cascade MTF	NA	Exogenous $CaCl_2$	Below	NA-x-Bβ
	Randelli et al.[91] (*Disabil Rehabil*, 2008)	IV	Case series, pilot study	PRP augmentation group (n = 14)	(+) Safe and effective, produces results that seem to be stable with time	Biomet GPS II	NA	Exogenous $CaCl_2$	Above	NA-x-Aα
	Barber et al.[92] (*Arthroscopy*, 2011)	III	Case-control study	PRP fibrin matrix group (n = 20) *v* control group (n = 20)	(+) A statistically significant reduction in retear rates (from 60% to 30%) was shown by addition of 2 PRP fibrin matrix constructs to rotator cuff tendon repair (P = .03)	Cascade MTF	NA	Endogenous type I collagen	Below	NA-Bβ
Subacromial decompression	Everts et al.[93] (*Eur Surg Res*, 2008)	I	Randomized controlled study	Platelet leukocyte gel group (n = 20) *v* control group (n = 20)	(+) Faster recovery, earlier return to daily activities, took less pain medication	Magellan	NA	Endogenous type I collagen	Above	NA-Aα
Cartilage regeneration/ OA	Kon et al.[94] (*Arthroscopy*, 2011)	II	Prospective comparative study	PRP group (n = 50, 3 injections) *v* HA low-molecular-weight group (n = 50, 3 injections) *v* HA high-molecular-weight group (n = 50) evaluated at 2 and 6 mo	(+) PRP greater and longer efficacy than HA injections	NA	6.8×10^6 6×	Exogenous $CaCl_2$	NA	P4-x-NA
	Kon et al.[95] (*Knee Surg Sports Traumatol Arthrosc*, 2010)	IV	Prospective case study	PRP group (n = 150)	(+) PRP potential to reduce pain and improve knee function and quality of life in younger patients with low degree of articular degeneration	NA	6.8×10^6 6×	Exogenous $CaCl_2$	NA	P4-x-NA
	Sánchez et al.[27] (*Clin Exp Rheumatol*, 2008)	IV	Observational retrospective cohort study	PRGF group (n = 30)	(+) Significant improvement of pain in 33.3% of patients at 2 mo	BTI/PRGF	NA	Endogenous type I collagen	Below	NA-Bβ
Anterior cruciate ligament reconstruction	Silva and Sampaio[96] (*Knee Surg Sports Traumatol Arthrosc*, 2009)	II	Prospective comparative study	PRP (n = 30) *v* without PRP (n = 10)	(Neutral) PRP with or without thrombin activation does not seem to accelerate tendon integration	Biomet GPS III	NA	Exogenous thrombin *v* no thrombin	Above	NA-x-Aα *v* NA-Aα
Total knee arthroplasty	Peerbooms et al.[97] (*Acta Orthop*, 2009)	I	Double-blind randomized controlled trial	Platelet gel group (n = 50) *v* control (n = 52)	(Neutral) Application to wound site did not promote wound healing; no effect on pain, knee function, or hemoglobin values	Biomet	NA	Exogenous $CaCl_2$ + thrombin	Above	NA-x-Aα

Abbreviations: $CaCl_2$, calcium chloride; HA, hyaluronic acid; NA, not applicable; OA, osteoarthritis; PRFM, platelet rich fibrin matrix.

*The data indicate a lack of reporting of platelet concentration, activation method, and WBC content among clinical studies. Of the 23 clinical publications cited, the PAW could only be indicated for 1 study. This clearly shows that adequate comparison between studies is virtually impossible, and documentation and adherence to a classification system are imperative.

FIGURE 1. PRP PAW classification system.

inclusion or exclusion of neutrophils will become an important variable, a subcategory for neutrophil count has been created for systems that concentrate WBCs. If neutrophils are included in the buffy coat, then α (above) is added. If neutrophils are filtered out, then β (below) is added. Therefore buffy-coat systems will have a designation of either Aα or Aβ in our system.

For example, a PRP preparation consisting of 900,000 platelets/μL with a total WBC and neutrophil content above baseline levels will be documented as P3-Aα.

Activation Method

Ultimately, researchers can choose to activate platelets endogenously or through the addition of an exogenous clotting factor to any commercially available system. Endogenous activation is not given a designation. However, if an exogenous external activator is used, it is documented with an x. Combining the previously described PRP preparation with this activation method will provide the complete classification: either P3-Aα for endogenous activation or P3-x-Aα for exogenous activation.

CONCLUSIONS

PRP continues to occupy both orthopaedic literature and the lay press, and more funding is being dedicated to unraveling its mysteries; a simple method for comparing published data based on the content of PRP needs to be established. Our system offers a simple, effective method for quickly documenting the cellular components and activation method used. The acronym PAW serves as a pneumonic for Platelets, Activation, and White cells, and the subcategories are thoughtfully organized to enhance recall. Using a classification system will speed the process of identifying the optimal PRP preparation for each indication and allow other investigators to replicate published data or perform meta-analyses.

REFERENCES

1. Woodell-May JE, Ridderman DN, Swift MJ, Higgins J. Producing accurate platelet counts for platelet rich plasma: Validation of a hematology analyzer and preparation techniques for counting. *J Craniofac Surg* 2005;16:749-759.

2. Brickson S, Ji LL, Schell K, Olabisi R, St Pierre Schneider B, Best TM. M1/70 attenuates blood-borne neutrophil oxidants, activation, and myofiber damage following stretch injury. *J Appl Physiol* 2003;95:969-976.

3. Crinnion JN, Homer-Vanniasinkam S, Parkin SM, Gough MJ. Role of neutrophil-endothelial adhesion in skeletal muscle reperfusion injury. *Br J Surg* 1996;83:251-254.

4. Diegelmann RF, Evans MC. Wound healing: An overview of acute, fibrotic and delayed healing. *Front Biosci* 2004;9:283-289.

5. Dovi JV, He LK, DiPietro LA. Accelerated wound closure in neutrophil-depleted mice. *J Leukoc Biol* 2003;73:448-455.

6. Grøgaard B, Gerdin B, Reikerås O. The polymorphonuclear leukocyte: Has it a role in fracture healing? *Arch Orthop Trauma Surg* 1990;109:268-271.

7. Martin P, Leibovich SJ. Inflammatory cells during wound repair: The good, the bad and the ugly. *Trends Cell Biol* 2005;15:599-607.

8. Schneider BS, Tiidus PM. Neutrophil infiltration in exercise-injured skeletal muscle: How do we resolve the controversy? *Sports Med* 2007;37:837-856.

9. Simpson DM, Ross R. The neutrophilic leukocyte in wound repair. A study with antineutrophil serum. *J Clin Invest* 1972;51:2009-2023.

10. Toumi H, Best TM. The inflammatory response: Friend or enemy for muscle injury? *Br J Sports Med* 2003;37:284-286.

11. Tidball JG. Inflammatory processes in muscle injury and repair. *Am J Physiol Regul Integr Comp Physiol* 2005;288:R345-R353.

12. Redler LH, Thompson SA, Hsu SH, et al. Platelet-rich plasma therapy: A systematic literature review and evidence for clinical use. *Phys Sports Med* 2011;39:42-51.

13. Kon E. PRP for the treatment of cartilage defects. Presented at the AAOS (American Academy of Orthopaedic Surgeons) Now 2011 PRP Forum, San Diego, CA, February 14, 2011.

14. Castillo TN, Pouliot MA, Kim HJ, Dragoo JL. Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. *Am J Sports Med* 2011;39:266-271.

15. Kon E, Filardo G, Di Martino A, Marcacci M. Platelet-rich plasma (PRP) to treat sports injuries: Evidence to support its use. *Knee Surg Sports Traumatol Arthrosc* 2011;19:516-527.

16. Wahlström O, Linder C, Kalén A, Magnusson P. Variation of pH in lysed platelet concentrates influence proliferation and alkaline phosphatase activity in human osteoblast-like cells. *Platelets* 2007;18:113-118.

17. Borg T, Modig J. Potential anti-thrombotic effects of local anesthetics due to their inhibition of platelet aggregation. *Acta Anaesthesiol Scand* 2008;29:739-742.

18. Mazzocca AD, McCarthy MB, Chowaniec DM, et al. Platelet-rich plasma differs according to preparation method and human variability. *J Bone Joint Surg Am* 2012;94:308-316.

19. Tanaka Y, Kurashima K, Saito H, et al. In vitro short-term platelet adhesion on various metals. *J Artif Organs* 2009;12:182-186.

20. Michelson AD. *Platelets*. Ed 2. San Diego: Elsevier/Academic Press; 2007.

21. Grottum KA, Jorgensen L, Jeremic M. Decrease in platelet surface charge during phagocytosis of polystyrene latex particles or thorium dioxide. *Scand J Haematol* 1972;9:83-96.

22. Arthrex. ACP: Autologous conditioned plasma double syringe system. Brochure LB0810F. Naples, FL: Arthrex, 2011.

23. Cascade Medical/MTF. Releasing the power of growth factor healing. Brochure 408-5M 506TC4. Edison, NJ: Cascade Medical/Musculoskeletal Transplant Foundation, 2008.

24. Leitner GC, Gruber R, Neumüller J, et al. Platelet content and

growth factor release in platelet-rich plasma: A comparison of four different systems. *Vox Sang* 2006;91:135-139.

25. Mazzucco L, Balbo V, Cattana E, Guaschino R, Borzini P. Not every PRP-gel is born equal. Evaluation of growth factor availability for tissues through four PRP-gel preparations: Fibrinet, RegenPRP-Kit, Plateltex, and one manual procedure. *Vox Sang* 2009;97:110-118.

26. Anitua E, Aguirre JJ, Algorta J, et al. Effectiveness of autologous preparation rich in growth factors for the treatment of chronic cutaneous ulcers. *J Biomed Mater Res B Appl Biomater* 2008;84:415-421.

27. Sánchez M, Anitua E, Azofra J, Aguirre JJ, Andia I. Intra-articular injection of an autologous preparation rich in growth factors for the treatment of knee OA: A retrospective cohort study. *Clin Exp Rheumatol* 2008;26:910-913.

28. Sánchez M, Anitua E, Azofra J, Andía I, Padilla S, Mujika I. Comparison of surgically repaired Achilles tendon tears using platelet-rich fibrin matrices. *Am J Sports Med* 2007;35:245-251.

29. Biomet. GPS III platelet separation system process steps. Brochure BB10001.0. Warsaw, IN: Biomet, 2009.

30. Biomet. GPS III platelet separation system. Brochure BB10003.0. Warsaw, IN: Biomet, 2007.

31. Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: Implications for wound healing. *Plast Reconstr Surg* 2004;114:1502-1508.

32. Kevy SV, Jacobson MS. Comparison of methods for point of care preparation of autologous platelet gel. *J Extra Corpor Technol* 2004;36:28-35.

33. Roukis TS, Zgonis T, Tiernan B. Autologous platelet-rich plasma for wound and osseous healing: A review of the literature and commercially available products. *Adv Ther* 2006;23:218.

34. Harvest Technologies. Developing technologies for accelerating healing, naturally. Brochure SL 021/0106. Plymouth, MA: Harvest Technologies, 2000.

35. Sclafani AP, Romo TR, Ukrainsky G, et al. Modulation of wound response and soft tissue ingrowth in synthetic and allogeneic implants with platelet concentrate. *Arch Facial Plast Surg* 2005;7:163-169.

36. Christensen K, Vang S, Brady C, et al. Autologous platelet gel: An in vitro analysis of platelet-rich plasma using multiple cycles. *J Extra Corpor Technol* 2006;38:249-253.

37. Medtronic. Magellan autologous platelet separator. Brochure UC200502505. Minneapolis, MN: Medtronic, 2005.

38. Exactech. Accelerate concentrating system platelet rich plasma preparation guide. Brochure 713-06-00 Rev B. Gainesville, FL: Exactech, 2010.

39. Exactech. Analysis of Accelerate platelet concentrating system: Preparation of concentrated platelet product. Brochure 713-06-81. Gainesville, FL: Exactech, 2010.

40. Exactech. Accelerate PRP sport preparation technique. Brochure 713-08-00 Rev B. Gainesville, FL: Exactech, 2010.

41. Sánchez M, Anitua E, Andia I. Poor standardization in platelet-rich therapies hampers advancement. *Arthroscopy* 2010;26:725-726.

42. Haynesworth SE, Kadiyala S, Liang LN, et al. Mitogenic stimulation of human mesenchymal stem cells by platelet release suggest a mechanism for enhancement of bone repair by platelet concentrates. Presented at the 48th Meeting of the Orthopedic Research Society, Boston, MA, 2002.

43. Anitua E, Andía I, Sanchez M, et al. Autologous preparations rich in growth factors promote proliferation and induce VEGF and HGF production by human tendon cells in culture. *J Orthop Res* 2005;23:281-286.

44. Anitua E, Orive G, Pla R, Roman P, Serrano V, Andía I. The effects of PRGF on bone regeneration and on titanium implant osseointegration in goats: A histologic and histomorphometric study. *J Biomed Mater Res A* 2009;91:158-165.

45. Anitua E, Sánchez M, Nurden AT, et al. Platelet-released growth factors enhance the secretion of hyaluronic acid and induce hepatocyte growth factor production by synovial fibroblasts from arthritic patients. *Rheumatology (Oxford)* 2007;46:1769-1772.

46. Anitua E, Sánchez M, Zalduendo MM, et al. Fibroblastic response to treatment with different preparations rich in growth factors. *Cell Prolif* 2009;42:162-170.

47. Sánchez M, Anitua E, Azofra J, Prado R, Muruzabal F, Andia I. Ligamentization of tendon grafts treated with an endogenous preparation rich in growth factors: Gross morphology and histology. *Arthroscopy* 2010;26:470-480.

48. Sánchez M, Anitua E, Cugat R, et al. Nonunions treated with autologous preparation rich in growth factors. *J Orthop Trauma* 2009;23:52-59.

49. Sánchez M, Azofra J, Anitua E, et al. Plasma rich in growth factors to treat an articular cartilage avulsion: A case report. *Med Sci Sports Exerc* 2003;35:1648-1652.

50. Graziani F, Ivanovski C, Cei S, Ducci F, Tonetti M, Gabriele M. The in vitro effect of different PRP concentrations on osteoblasts and fibroblasts. *Clin Oral Implants Res* 2006;17:212-219.

51. Torricelli P, Fini M, Filardo G, et al. Regenerative medicine for the treatment of musculoskeletal overuse injuries in competition horses. *Int Orthop* 2011;35:1569-1576.

52. He HT, Majd ME, Holt RT, et al. Do autologous growth factors enhance transforaminal lumbar interbody fusion? *Eur Spine J* 2003;12:400-407.

53. Weibrich G, Hansen K, Kleis W, Buch R, Hitzler WE. Effect of platelet concentration in platelet-rich plasma on peri-implant bone regeneration. *Bone* 2004;34:665-671.

54. Giusti I, Rughetti A, D'Ascenzo S, et al. Identification of an optimal concentration of platelet gel for promoting angiogenesis in human endothelial cells. *Transfusion* 2009;49:771-778.

55. Gruber R, Varga F, Fischer MB, Watzek G. Platelets stimulate proliferation of bone cells: Involvement of platelet-derived growth factor, microparticles and membranes. *Clin Oral Implants Res* 2002;13:529-535.

56. Choi BH, Zhu SJ, Kim BY, et al. Effect of platelet-rich plasma (PRP) concentration on the viability and proliferation of alveolar bone cells: An in vitro study. *Int J Oral Maxillofac Surg* 2005;34:420-424.

57. Nikolidakis D, Jansen JA. The biology of platelet-rich plasma and its application in oral surgery: Literature review. *Tissue Eng Part B Rev* 2008;14:249-258.

58. Jo CH, Roh YH, Kim JE, et al. Optimizing platelet-rich plasma gel formation by varying time and gravitational forces during centrifugation. *J Oral Implantol* in press, available online 11 April, 2011.

59. Barrett S, Erredge S. Growth factors for chronic plantar fasciitis. *Podiatry Today* 2004;17:37-42.

60. Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: From pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). *Trends Biotechnol* 2009;27:158-167.

61. Saad Setta H, Elshahat A, Elsherbiny K, Massoud K, Safe I. Platelet-rich plasma versus platelet-poor plasma in the management of chronic diabetic foot ulcers: A comparative study. *Int Wound J* 2011;8:307-312.

62. Rappl LM. Effect of platelet rich plasma gel in a physiologically relevant platelet concentration on wounds in persons with spinal cord injury. *Int Wound J* 2011;8:187-195.

63. Frykberg RG, Driver VR, Carman D, et al. Chronic wounds treated with a physiologically relevant concentration of platelet-rich plasma gel: A prospective case series. *Ostomy Wound Manage* 2010;56:36-44.

64. Moojen DJ, Everts PA, Schure RM, et al. Antimicrobial activity of platelet-leukocyte gel against Staphylococcus aureus. *J Orthop Res* 2008;26:404-410.

65. Martin P, D'Souza D, Martin J, et al. Wound healing in the PU.1 null mouse—Tissue repair is not dependent on inflammatory cells. *Curr Biol* 2003;13:1122-1128.

66. de Vos RJ, Weir A, van Schie HT, Verhaar JA, Weinans H, van Schie HT. No effects of PRP on ultrasonographic tendon structure and neovascularisation in chronic midpoint Achilles tendinopathy. *Br J Sports Med* 2011;45:387-392.

67. Mishra A, Woodall J, Vieira A. Treatment of tendon and muscle using platelet-rich plasma. *Clin Sports Med* 2009;28:113-125.

68. Harrison S, Vavken P, Kevy S, Jacobson M, Zurakowski D, Murray MM. Platelet activation by collagen provides sustained release of anabolic cytokines. *Am J Sports Med* 2011;39:729-734.

69. Mosesson MW, Siebenlist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. *Ann N Y Acad Sci* 2001;936:11-30.

70. Alsousou J, Thompson M, Hulley P, Noble A, Willett K. The biology of platelet-rich plasma and its application in trauma and orthopaedic surgery: A review of the literature. *J Bone Joint Surg Br* 2009;91:987-996.

71. Dohan DM, Choukroun J, Diss A, et al. Platelet-rich fibrin (PRF): A second-generation platelet concentrate. Part I: Technological concepts and evolution. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2006;101:e37-e44.

72. Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA. Platelet-rich plasma: From basic science to clinical applications. *Am J Sports Med* 2009;37:2259-2272.

73. Bir SC, Esaki J, Marui A, et al. Angiogenic properties of sustained release platelet-rich plasma: Characterization in-vitro and in the ischemic hind limb of the mouse. *J Vasc Surg* 2009;50:870-879.e2.

74. Batoni G, Maisetta G, Brancatisano FL, Esin S, Campa M. Use of antimicrobial peptides against microbial biofilms: Advantages and limits. *Curr Med Chem* 2011;18:256-279.

75. Carrol RJ, Arnoczky SP, Graham S, et al. Characterization of autologous growth factors. Cascade® platelet-rich fibrin matrix (PRFM). Edison, NJ: Musculoskeletal Transplant Foundation, 2005.

76. Fufa D, Shealy B, Jacobson M, Kevy S, Murray MM. Activation of platelet-rich plasma using soluble type I collagen. *J Oral Maxillofac Surg* 2008;66:684-690.

77. Lyras DN, Kazakos K, Georgiadis G, et al. Does a single application of PRP alter the expression of IGF-I in the early phase of tendon healing? *J Foot Ankle Surg* 2011;50:276-282.

78. Hechtman KS, Uribe JW, Botto-vanDemden A, Kiebzak GM. Platelet-rich plasma injection reduces pain in patients with recalcitrant epicondylitis. *Orthopedics* 2011;34:92-92.

79. Thanasas C, Papadimitriou G, Charalambidis C, Paraskevopoulos I, Papanikolaou A. Platelet-rich plasma versus autologous whole blood for the treatment of chronic lateral elbow epicondylitis: A randomized controlled clinical trial. *Am J Sports Med* 2011;39:2130-2134.

80. Peerbooms JC, Sluimer J, Bruijn DJ, Gosens T. Positive effect of an autologous platelet concentrate in lateral epicondylitis in a double-blind randomized controlled trial: Platelet-rich plasma versus corticosteroid injection with a 1-year follow-up. *Am J Sports Med* 2010;38:255-262.

81. Gosens T, Peerbooms JC, van Laar W, den Oudsten BL. Ongoing positive effect of platelet-rich plasma versus cortico-steroid injection in lateral epicondylitis: A double-blind randomized controlled trial with 2-year follow-up. *Am J Sports Med* 2011;39:1200-1208.

82. Mishra A, Pavelko T. Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. *Am J Sports Med* 2006;34:1774-1778.

83. de Jonge S, de Vos RJ, Weir A, et al. One-year follow-up of platelet-rich plasma treatment in chronic Achilles tendinopathy: A double-blind randomized placebo-controlled trial. *Am J Sports Med* 2011;39:1623-1629.

84. Schepull T, Kvist J, Norrman H, Trinks M, Berlin G, Aspenberg P. Autologous platelets have no effect on the healing of human Achilles tendon ruptures: A randomized single-blind study. *Am J Sports Med* 2011;39:38-47.

85. Filardo G, Presti ML, Kon E, Marcacci M. Nonoperative biological treatment approach for partial Achilles tendon lesion. *Orthopedics* 2010;33:120-123.

86. Filardo G, Kon E, Della Villa S, Vincentelli F, Fornasari PM, Marcacci M. Use of platelet-rich plasma for the treatment of refractory jumper's knee. *Int Orthop* 2010;34:909-915.

87. Kon E, Filardo G, Delcogliano M, et al. Platelet-rich plasma: New clinical application: A pilot study for treatment of jumper's knee. *Injury* 2009;40:598-603.

88. Jo CH, Kim JE, Yoon KS, et al. Does platelet-rich plasma accelerate recovery after rotator cuff repair? A prospective cohort study. *Am J Sports Med* 2011;39:2082-2090.

89. Randelli P, Arrigoni P, Ragone V, Aliprandi A, Cabitza P. Platelet rich plasma in arthroscopic rotator cuff repair: A prospective RCT study, 2-year follow-up. *J Shoulder Elbow Surg* 2011;20:518-528.

90. Castricini R, Longo UG, De Benedetto M, et al. Platelet-rich plasma augmentation for arthroscopic rotator cuff repair: A randomized controlled trial. *Am J Sports Med* 2011;39:258-265.

91. Randelli PS, Arrigoni P, Cabitza P, Volpi P, Maffulli N. Autologous platelet rich plasma for arthroscopic rotator cuff repair. A pilot study. *Disabil Rehabil* 2008;30:1584-1589.

92. Barber FA, Hrnack SA, Snyder SJ, Hapa O. Rotator cuff repair healing influenced by platelet-rich plasma construct augmentation. *Arthroscopy* 2011;27:1029-1035.

93. Everts PA, Devilee RJ, Brown Mahoney C, et al. Exogenous application of platelet-leukocyte gel during open subacromial decompression contributes to improved patient outcome. A prospective randomized double-blind study. *Eur Surg Res* 2008;40:203-210.

94. Kon E, Mandelbaum B, Buda R, et al. Platelet-rich plasma intra-articular injection versus hyaluronic acid viscosupplementation as treatments for cartilage pathology: From early degeneration to osteoarthritis. *Arthroscopy* 2011;27:1490-1501.

95. Kon E, Buda R, Filardo G, et al. Platelet-rich plasma: Intra-articular knee injections produced favorable results on degenerative cartilage lesions. *Knee Surg Sports Traumatol Arthrosc* 2010;18:472-479.

96. Silva A, Sampaio R. Anatomic ACL reconstruction: Does the platelet-rich plasma accelerate tendon healing? *Knee Surg Sports Traumatol Arthrosc* 2009;17:676-682.

97. Peerbooms JC, de Wolf GS, Colaris JW, Bruijn DJ, Verhaar JA. No positive effect of autologous platelet gel after total knee arthroplasty. *Acta Orthop* 2009;80:557-562.